Dear Investors,
We cordially invite you to attend WuXi AppTec's Q1 2022 Results Exchange Conference Call, please call the phone number below.
The Chinese meeting will be held on April 26, 2022 from 9:00 to 9:50 a.m. Beijing time
The English conference will be held on April 26, 2022 from 8:00-8:50 a.m. Beijing time
*For non-whitelisted users, please pre-register via the link in the poster.
Dear Investors,
WuXi AppTec is pleased to invite you to our 1Q22 Results Webcast. We thank you for your interest and we sincerely hope you will join us.
English Webcast at 8:00-8:50 a.m., April 26, China time (8:00-8:50 p.m., April 25, 2022, EST)
Chinese Webcast at 9:00-9:50 a.m., April 26, China time
*Please sign up in advance for the English webcast through the link on the poster.
About WuXi AppTec
WuXi AppTec (stock code: 603259.SH/2359.HK) provides integrated, end-to-end new drug development and manufacturing services for the global biopharmaceutical industry, with operating bases in Asia, Europe and North America. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers the threshold of R&D, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patients, covering the fields of chemical drug development and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production. In 2021, WuXi AppTec was rated an ESG (Environmental, Social and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D and innovation projects of more than 5,700 partners from more than 30 countries around the world, and is committed to bringing more new drugs and good drugs to patients around the world, and realizing the vision of "making no difficult drugs and incurable diseases in the world" as soon as possible.
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,700 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
![Accelerate the layout of the hydrogen fuel cell track! GM plans to develop hydrogen-fueled mobile power generation equipment[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)